EDAP TMS S.A. to Present 10-Year Results, Live Ablatherm Treatments at EAU Congress

Distributor Meeting, User Group Sessions, Media Conferences to Highlight Ablatherm-HIFU 


LYON, France, March 21  /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and distribution of a wide portfolio of minimally invasive medical devices primarily for the treatment of urological diseases announced its participation plans for the European Association of Urology (EAU) Congress in Berlin March 21-23, 2007.

EDAP's participation in the EAU event opening today will be the largest of any HIFU company and include:

   *  A Gold Sponsorship of the Congress giving EDAP high visibility to
      participants,
   *  Presentation of numerous HIFU sessions and posters in the conference
      proceedings,
   *  A dedicated "Ablatherm-HIFU Symposium" chaired by Pr. Aus, of
      Goteberg, Sweden, Chairman of the "EAU Guidelines Office" in charge of
      establishing guidelines for the use of new therapies in Europe,
   *  Release of 10-year outcomes for Ablatherm efficacy and safety, the
      longest clinical follow-up in HIFU for localized prostate cancer,
   *  Live treatment sessions at Franziskus Krankenhaus, and Charite Berlin
      available for direct attendance by urologists as well as video
      broadcast back to the congress site, and
   *  A press conference open to all European journalists attending the
      congress and representing specialized healthcare, senior living, and
      the general public audiences, where Ablatherm technology will be
      presented together with its outstanding long-term clinical results.



EDAP hosted a preconference distributor meeting for its more than 40 sales and marketing partners, mainly in Europe.  This dedicated event clearly strengthened the long-term relationship with EDAP's partners who are confident in the success of Ablatherm-HIFU based on their experience, networking, and direct market knowledge of their regions.  Above all, they are absolutely convinced they have the best and safest technology to treat localized prostate cancer while preserving patient quality of life.

Marc Oczachowski, Chief Operating Officer of EDAP TMS stated, "We took the opportunity of the annual EAU Congress to organize a dedicated meeting to gather our direct sales force and partners to reiterate our strong strategy, particularly our focus on expanding the Ablatherm-HIFU RPP business in key European countries, while sharing with them all of our innovative marketing and sales programs recently developed.  Our distributors and partners are all the more motivated and committed upon presentation of our RPP successes in key European countries.  We clearly see that this model is perfectly adapted for countries where EDAP is directly addressing the market and also for regions where we partner.  Our sales and distributor teams are strongly committed to EDAP and making Ablatherm-HIFU a success as a new standard of care in localized prostate cancer."

EDAP also hosted an external media conference at the Continental Hotel Berlin as part of its ongoing European public relations and marketing program aimed at securing high visibility of Ablatherm-HIFU for both patients and doctors.  Journalists attending the conference as well as the regional media were all invited to interact with experienced HIFU practitioners as well as discuss the patient experience with a local gentleman treated five years ago with positive outcomes in preserving his quality of life as compared to his other treatment options.  Available to discuss Ablatherm-HIFU long term data were Drs. Miller and Schostak of Charite Berlin and Drs. Blana and Wieland from Regensburg University.

Oczachowski stated, "This press conference was a real success with many journalists attending.  Our marketing and education efforts will make more people aware of these benefits uniquely available on Ablatherm-HIFU.  This year we will set a new standard with the presentation of our 10-year study results showing Ablatherm's high efficacy and low side effects, giving patients and their doctors full confidence in EDAP's ability to provide a new level of care.  We look forward to a successful EAU event and will report its outcomes at the closing of the congress."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer.  HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects.  Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment.  The company is also developing this technology for the potential treatment of certain other types of tumors.  EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Magnolia Investor Relations at [phone], the Corporate Investor Relations Dept at [phone] or see the Company's Web sites at http://www.edap-tms.com/ and http://www.hifu-planet.com/ .

   To sign up for alerts please visit:
   http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0



In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties.  These include statements regarding the Company's growth and expansion plans.  Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements.  Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission.  Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

   CONTACT:  EDAP TMS S.A.            Magnolia Investor Relations
             Blandine Confort         Matt Kreps
             [phone]        972 801 4900


DATASOURCE: EDAP TMS S.A.



CONTACT:  Blandine Confort of EDAP TMS S.A., [phone]; or Matt

Kreps of Magnolia Investor Relations, [phone], for EDAP TMS S.A.



Web site:  http://www.edap-tms.com/

http://www.hifu-planet.com/

http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0 

Copyright